EPi-Sense Guided Coagulation System
AtriCure, Inc. · Decision date Oct 7, 2025
What did the FDA approve?
FDA records P200002/S012 as a supplement to PMA P200002, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Oct 7, 2025.
FDA approval order statement
approval of a revised protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P200002.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 7, 2025
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P200002/S012
- Regulatory pathway
- PMA supplement
- Applicant
- AtriCure, Inc.
- Product code
- OCM
- Decision code
- APPR
- Decision date
- Oct 7, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Surgical cardiac ablation device, for treatment of atrial fibrillation.
- Applicant
- AtriCure, Inc.
- Product code
- OCM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P200002. Subsequent supplements may change the device or its indications.
FDA decision timeline
P200002 · Original PMA
EPi-Sense Guided Coagulation System
P200002/S012 received
Application receipt date recorded by FDA.
P200002/S012 · FDA decision
Normal 180 Day Track No User Fee
P200002/S013 · Related supplement
EPi-Sense ST Coagulation System
P200002/S014 · Related supplement
EPi-Sense and EPi-Sense ST Guided Coagulation System
P200002/S015 · Related supplement
EPi- Sense ST Coagulation System
Timeline entries are records held by MedtechLedger for P200002. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200002
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| AtriCure, Inc. | PMA approval | Apr 28, 2021 | FDA | |
EPi-Sense ST Coagulation SystemP200002/S013 | AtriCure, Inc. | PMA supplement | Nov 14, 2025 | FDA |
| AtriCure, Inc. | PMA supplement | May 6, 2026 | FDA | |
EPi- Sense ST Coagulation SystemP200002/S015 | AtriCure, Inc. | PMA supplement | Sep 24, 2026 | FDA |
Explore the linked device profile
Other records with product code OCM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Synergy Ablation SystemP100046/S021 | AtriCure, Inc. | PMA supplement | Sep 24, 2026 | FDA |
Synergy Ablation SystemP100046/S020 | AtriCure, Inc. | PMA supplement | May 6, 2026 | FDA |
| AtriCure, Inc. | PMA approval | Dec 14, 2011 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
AtriCure, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 7555 Innovation Way, Mason, OH, 45040
Sources and methodology
- Original FDA record: P200002/S012
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



